Veraxa Biotech (NASDAQ:VRXA) Stock: Insider Christoph Samuel Ziegler Buys 30,000 Shares

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Christoph Samuel Ziegler purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The stock was bought at an average cost of $1.09 per share, for a total transaction of $32,700.00. Following the acquisition, the director owned 37,932 shares in the company, valued at approximately $41,345.88. The trade was a 378.21% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Veraxa Biotech Stock Down 2.8%

NASDAQ:VRXA opened at $1.03 on Friday. Veraxa Biotech Holding AG has a 12-month low of $0.99 and a 12-month high of $27.36.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Veraxa Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 31st.

About Veraxa Biotech

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.